Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.
StivargaŽ is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.
Media Articles Related to Stivarga (Regorafenib)
SMC accepts Stivarga (regorafenib) for use in Scotland for the treatment of adult patients with gastrointestinal stromal tumours (GIST)
Source: Cancer / Oncology News From Medical News Today [2015.04.14]
The Scottish Medicines Consortium (SMC) has announced that Stivarga® (regorafenib) has been accepted for use within NHS Scotland for the treatment of adult patients with unresectable or...
Clinical Trials Related to Stivarga (Regorafenib)
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma [Not yet recruiting]
This clinical study evaluates the efficacy and safety of regorafenib in patients with
advanced liver cancer who have progressed on sorafenib treatment.
Approximately 530 patients who meet the entry criteria will be randomly assigned in a 2: 1
ratio to regorafenib or placebo (1/3 chance to receive placebo).
Primary endpoint of the study is overall survival.
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines [Not yet recruiting]
Regorafenib has been proved to improved survival in patients with metastatic colorectal
cancer who have been failed to all of known standard chemotherapy (The CORRECT study). The
phase Ib study of regorafenib plus FOLFOX or FOLFIRI was performed and the dose of
regorafenib was fixed; 160 mg/day on days 4 to 10 (7 days per cycle when combined with
FOLFOX or FOLFIRI). Regorafenib plus FOLFOX as second-line chemotherapy in mCRC patients who
progressed after first-line irinotecan-based chemotherapy has not been studied yet, and
because there have been unmet needs for the discovery of valid targeted agent combination
for the second-line FOLFOX as above reasons, the investigators planned this study of
regorafenib plus FOLFOX as second-line chemotherapy in mCRC patients who progressed after
first-line irinotecan-based chemotherapy.
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy [Recruiting]
The purpose of this study is to assess if Regorafenib in combination with best supportive
care will slow down tumor progression and result in increased survival in patients with
metastatic colorectal cancer.
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy [Available]
This is a phase III B, prospective, interventional, open-label, single-arm, multicenter
study to provide regorafenib to subjects diagnosed with metastatic colorectal cancer who
have failed after standard therapy and for whom no therapy alternatives exist, in the time
between positive results and approval / availability on the market, and to collect safety
data for regorafenib until market access.
Regorafenib is an oral (i. e. taken by mouth) multi-targeted kinase inhibitor. A kinase
inhibitor targets certain key proteins that are essential for the survival of the cancer
cell. By specifically targeting these proteins, regorafenib may stop cancer growth. The
growth of the tumor may be decreased by preventing these specific proteins from functioning.
The primary endpoint of this study will be safety.
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy [Available]
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic
and / or unresectable GIST who have progressed after standard therapy.
Selected additional safety information on regorafenib will be collected and progression-free
survival (PFS) will be estimated.